About Us
Overview
Management Team
Board of Directors
Our Founders
Technologies
IMMUNE FX (IFX): Personalized Cancer Vaccines
Bi-Functional Antibody Drug Conjugates (ADCs)
Scientific Publications
Pipeline
Overview
IFx-2.0
IFx-3.0
ADC: Nal – anti TIGIT
Clinical Studies
IFX-2.0: Phase 3 Registration Trial
Investors
Overview
Press Releases
Events
Company Information
Overview
Management Team
Stock Information
SEC Filings
Corporate Governance
Overview
Board of Directors
IR Contacts
E-mail Alerts
News
Press Releases
E-mail Alerts
Contact Us
Select Page
Investors
|
Press Releases
